Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme
How this was made
The 30-second read
Why it matters
The 8‑K provides the first regulatory clearance for the combination and detailed Phase 2 efficacy data, which are key milestones for the upcoming Phase 3 trial.
Market read
The filing adds material clinical and regulatory milestones that could move Agenus' stock and influence the broader oncology biotech space.
What to watch
The $85 M private placement dilutes existing shareholders and may limit near‑term cash runway.
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Agenus reported a third consecutive quarter of positive operating income and increased cash following the July private placement, while total revenue and pre-commercial product revenue declined sequentially and most reported revenue was non-cash royalty revenue.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q1 2026 pre-commercial product revenueother | $4.6M | – | – |
| Q2 2026 pre-commercial product revenueother | $6.4M | – | – |
| Q3 2026 pre-commercial product revenueother | $6M | – | – |
| First nine months of 2026 pre-commercial product revenueother | $17M | – | – |
| Q1 2026 non-cash royalty revenueother | 29.1 | – | – |
| Q2 2026 non-cash royalty revenueother | 28.1 | – | – |
| Q3 2026 non-cash royalty revenueother | $25.5M | – | – |
| First nine months of 2026 non-cash royalty revenueother | 82.7 | – | – |
| Q3 2025 service and other revenueother | 1.1 | – | – |
| First nine months of 2025 service and other revenueother | 2.5 | – | – |
| Q1 2026 total revenueother | $33.7M | – | – |
| Q2 2026 total revenueother | $34.5M | – | – |
| Q3 2026 total revenueother | $31.5M | – | – |
| First nine months of 2026 total revenueother | $99.7M | – | – |
| Q1 2026 operating incomeother | $15.1M | – | – |
| Q2 2026 operating incomeother | $11.3M | – | – |
| Q3 2026 operating incomeother | $11.4M | – | – |
| First nine months of 2026 operating incomeother | $37.8M | – | – |
| Q1 2026 net incomeother | $39.2M | – | – |
| Q2 2026 net lossother | $(0.6 million) | – | – |
| Q3 2026 net incomeother | $2.8M | – | – |
| First nine months of 2026 net incomeother | $41.4M | – | – |
| Q1 2026 cash, cash equivalents and short-term investmentsother | $35M | – | – |
| Q2 2026 cash, cash equivalents and short-term investmentsother | $18.7M | – | – |
| September 30, 2026 cash, cash equivalents and short-term investmentsother | $86.9M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Pre-commercial BOT+BAL product revenueRevenue was generated from global patient access programs, including France’s AAC program and physician-initiated paid named-patient programs. | $6M | – | – |
| Non-cash royalty revenueNon-cash royalty revenue relates to royalty interests Agenus previously monetized and does not generate cash for the company. | $25.5M | – | – |
Q1 2027 through year-end 2031 outlook
- NoteFirst patient dosing anticipated in the first quarter of 2027.
- NoteROBBIN is designed to enroll approximately 850 patients.
- NoteAn interim pathologic response assessment of the first 100 patients enrolled is anticipated in Q4 of 2027.
- NoteBased on the current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027.
- NoteAssuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031.
- NoteQ2 2027: Anticipated 60 patients enrolled in ROBBIN (Series A Warrants milestone).
- NoteSecond half of 2027: Anticipated interim pathologic response assessment from ROBBIN (Series B Warrants milestone).
- NoteThe milestone-aligned warrants could provide up to approximately $255 million in additional gross proceeds if fully exercised.
What drove it
- Pre-commercial BOT+BAL product revenue was $6.0 million in the third quarter of 2026 from global patient access programs.
- Armenia granted the first marketing authorizations for Botvymo® and Evamplix® shortly after quarter-end.
- NEST reported a 32% pathologic complete response rate in MSS tumors, while UNICORN reported a 29% pathologic complete response rate and 36% major pathologic response rate in its MSS BOT+BAL cohort.
- ROBBIN site qualification and startup activities are advancing toward first patient dosing anticipated in the first quarter of 2027.
Concerns
- Total revenue included $25.5 million of non-cash royalty revenue, which does not generate cash for the company.
- Pre-commercial BOT+BAL product revenue declined from $6.4 million in the second quarter of 2026 to $6.0 million in the third quarter of 2026.
- Recognized revenue from access programs can vary with country-specific pricing, reimbursement, taxation, distribution arrangements and timing, and does not necessarily move in proportion to physician inquiries or patient treatment activity.
- The Armenian marketing authorizations are conditional and valid for one year, with renewal based on annual clinical updates provided to the regulator.
- BOT+BAL remains investigational outside Armenia and is not approved by the U.S. Food and Drug Administration.
What to watch
- November 2026 BOT+BAL long-term survivor characteristics and translational research presentations at SITC 2026.
- Q1 2027 ROBBIN Phase 3 initiation and first patient enrollment.
- Q2 2027 anticipated 60 patients enrolled in ROBBIN, the Series A Warrants milestone.
- Second half of 2027 anticipated interim pathologic response assessment from ROBBIN, the Series B Warrants milestone.
- Potential additional regulatory submissions in 2027.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments were $86.9 million at September 30, 2026, compared with $18.7 million at June 30, 2026.
- The oversubscribed private placement completed in July provided approximately $85 million in upfront gross proceeds.
- The private placement includes milestone-aligned warrants that provide up to approximately $255 million in additional gross proceeds if fully exercised.
Analysis
Third-quarter total revenue was $31.5 million, compared with $30.2 million for the third quarter of 2025 and $34.5 million in the second quarter of 2026. The quarter included $6.0 million of pre-commercial BOT+BAL product revenue and $25.5 million of non-cash royalty revenue. The company states that royalty revenue relates to monetized royalty interests and does not generate cash, making the product-revenue line and its access-program variability important for assessing commercial demand.
Operating income was $11.4 million, compared with an operating loss of $4.6 million in the third quarter of 2025, marking the third consecutive quarter of positive operating income. Net income was $2.8 million, following net income of $39.2 million in Q1 2026 and a net loss of $0.6 million in Q2 2026. For the first nine months of 2026, total revenue was $99.7 million, operating income was $37.8 million, and net income was $41.4 million.
Liquidity increased to $86.9 million at September 30, 2026 from $18.7 million at June 30, 2026, following a July private placement that provided approximately $85 million in upfront gross proceeds. The financing also includes milestone-aligned warrants that could provide up to approximately $255 million in additional gross proceeds if fully exercised. Management expects the upfront proceeds to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027, while full warrant exercise is expected to support the planned ROBBIN program and operations through year-end 2031.
The operating and strategic focus is ROBBIN, the randomized Phase 3 study designed to enroll approximately 850 patients with high-risk Stage II and Stage III MSS colon cancer. First patient dosing is anticipated in the first quarter of 2027, with an interim pathologic response assessment of the first 100 patients anticipated in Q4 of 2027. Clinical support cited in the release includes NEST’s 32% pathologic complete response rate and UNICORN’s 29% pathologic complete response rate in MSS BOT+BAL cohorts. Armenia’s conditional one-year marketing authorizations establish the first approved pathway for BOT+BAL, while the company continues to describe the combination as investigational outside Armenia.
Management, verbatim
We have moved beyond planning ROBBIN to mobilizing investigators and activating sites around the world in preparation for patient enrollment.
Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus
At the same time, patients with advanced cancer need better options today. We continue to see growing international demand for BOT+BAL through France’s AAC program and physician-initiated named-patient programs.
Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus
Not in the filing
stated, not guessed- GAAP and non-GAAP designations for the reported financial metrics
- Gross profit and gross margin
- Operating expenses
- Income tax expense and tax rate
- GAAP and non-GAAP earnings per share
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases and dividends
- Explicit financial revenue, margin, operating-expense, tax-rate or EPS guidance
- Prior outlook for comparison
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Agenus (NASDAQ: AGEN) is a clinical‑stage immuno‑oncology company developing botensilimab (BOT) and balstilimab (BAL).
Ticker impact
Agenus filed an 8‑K reporting Q3 2026 results, first marketing authorizations for BOT+BAL and new Phase 3 ROBBIN trial data.
upward pressure as investors price in expanded market opportunity and upcoming Phase 3 enrollment.
First authorizations and strong pathologic response rates are material catalysts; the company also disclosed $17 M pre‑commercial revenue and a sizable cash position.
Market effects
Immuno‑oncology biotech sector may see broader investor interest.
US biotech market could experience modest gains.
Global oncology pipeline outlook is enhanced by new neoadjuvant data.
Counterpoint
If Phase 3 enrollment delays or safety issues arise, the stock could face downside despite early data.
Key entities
- companyAgenus Inc.
Biotech firm developing BOT+BAL immunotherapy.
- clinical_trialROBBIN Phase 3
Global randomized trial evaluating neoadjuvant BOT+BAL in MSS colon cancer.
